LCO \\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx
1 of 29
General Assembly Substitute Bill No. 1102
January Session, 2023
AN ACT CONCERNING PHARMACIES AND PHARMACISTS.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:
Section 1. Section 20-571 of the general statutes is repealed and the 1
following is substituted in lieu thereof (Effective July 1, 2023): 2
As used in this chapter and sections 2 to 4, inclusive, of this act, 3
unless the context otherwise requires: 4
(1) "Administer" or ["Administration"] "administration" means the 5
direct application of a drug or device to the body of a patient or 6
research subject by injection, inhalation, ingestion or any other means; 7
(2) "Automated prescription dispensing machine" means a device 8
and associated software operated by a pharmacy or a pharmacy that is 9
registered as a nonresident pharmacy pursuant to section 20-627, in a 10
nursing home or skilled nursing facility licensed pursuant to sections 11
19a-490 and 19a-491, that packages and labels patient-specific 12
medication or multiple medications for the purposes of administration 13
by a registered nurse or a licensed practical nurse based on a 14
prescription that has completed final verification by a licensed 15
pharmacist; 16
(3) "Care-giving institution" means an institution that provides 17
medical services and is licensed, operated, certified or approved by the 18 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
2 of 29
Commissioner of Public Health, the Commissioner of Developmental 19
Services or the Commissioner of Mental Health and Addiction 20
Services; 21
(4) "Commission" means the Commission of Pharmacy appointed 22
under the provisions of section 20-572; 23
(5) "Commissioner" means the Commissioner of Consumer 24
Protection; 25
(6) "Compound" means to combine, mix or put together two or 26
more ingredients pursuant to a prescription and includes the 27
preparation of drugs or devices in anticipation of prescriptions based 28
on routine, regularly-observed prescribing patterns; 29
(7) "Correctional or juvenile training institution" means a facility for 30
the detention or incarceration of persons convicted or accused of 31
crimes or offenses or for training of delinquent juveniles, including 32
those state facilities under the jurisdiction of the Commissioner of 33
Correction, training schools for delinquent juveniles and any other 34
facilities operated by the state or municipalities for such detention, 35
incarceration or training; 36
(8) "Device" means instruments, apparatuses and contrivances, 37
including their components, parts and accessories, intended: (A) [for] 38
For use in the diagnosis, cure, mitigation, treatment or prevention of 39
disease in humans or other animals; [,] or (B) to affect the structure or 40
any function of the body of humans or other animals, but does not 41
mean contact lenses; 42
(9) "Department" means the Department of Consumer Protection; 43
(10) "Deprescribing" means the systematic process of identifying 44
and discontinuing drugs in instances in which existing or potential 45
harms outweigh existing or potential benefits within the context of an 46
individual patient's care goals, current level of functioning, life 47
expectancy, values and preferences; 48 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
3 of 29
(11) "Dispense" means those acts of processing a drug or device for 49
delivery or for administration for a patient pursuant to a prescription 50
consisting of: (A) Comparing the directions on the label with the 51
directions on the prescription to determine accuracy; (B) the selection 52
of the drug or device from stock to fill the prescription; (C) the 53
counting, measuring, compounding or preparation of the drug or 54
device; (D) the placing of the drug or device in the proper container; 55
(E) the affixing of the label to the container; and (F) the addition to a 56
written prescription of any required notations. "Dispense" does not 57
include the acts of delivering a drug or device to a patient or of 58
administering the drug or device to the patient; 59
(12) "Dispensing outpatient facility" means a facility operated by a 60
corporation or municipality which provides medical services to 61
patients on an outpatient basis and which maintains stocks of drugs 62
for dispensing of drugs on a regular basis to patients for use off the 63
premises; 64
(13) "Drug" means: (A) [an] An article recognized in the official 65
United States Pharmacopoeia, official Homeopathic Pharmacopoeia of 66
the United States or official National Formulary, or any supplement to 67
any of them; [,] (B) an article intended for use in the diagnosis, cure, 68
mitigation, treatment or prevention of disease in humans or other 69
animals; [,] (C) an article, other than food, intended to affect the 70
structure or any function of the body of humans or any other animal; 71
[,] and (D) an article intended for use as a component of any article 72
specified in this subdivision, but does not include a device; 73
(14) "Health care institution" means institution, as defined in section 74
19a-490; 75
(15) "Health care institutional pharmacy" means an institutional 76
pharmacy located within a health care institution; 77
[(14)] (16) "Institutional pharmacy" means that area within a care-78
giving institution or within a correctional or juvenile training 79 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
4 of 29
institution, commonly known as the pharmacy, that is under the direct 80
charge of a pharmacist and in which drugs are stored and dispensed; 81
[(15)] (17) "Legend device" means a device that is required by 82
applicable federal or state law to be dispensed pursuant only to a 83
prescription or is restricted to use by prescribing practitioners only or 84
that, under federal law, is required to bear either of the following 85
legends: (A) "RX ONLY" IN ACCORDANCE WITH GUIDELINES 86
ESTABLISHED IN THE FEDERAL FOOD, DRUG AND COSMETIC 87
ACT; or (B) "CAUTION: FEDERAL LAW RESTRICTS THIS DEVICE 88
FOR USE BY OR ON THE OR DER OF A LICENSED 89
VETERINARIAN."; 90
[(16)] (18) "Legend drug" means a drug that is required by any 91
applicable federal or state law to be dispensed pursuant only to a 92
prescription or is restricted to use by prescribing practitioners only, or 93
means a drug that, under federal law, is required to bear either of the 94
following legends: (A) "RX ONLY" IN ACCORDANCE WITH 95
GUIDELINES ESTABLISHED IN THE FEDERAL FOOD, DRUG AND 96
COSMETIC ACT; or (B) "CAUTION: FEDERAL LAW RESTRICTS 97
THIS DRUG FOR USE BY OR ON THE ORDER OF A L ICENSED 98
VETERINARIAN."; 99
[(17)] (19) "Medical device and oxygen provider" means a person 100
who distributes devices or oxygen pursuant to a medical order or 101
prescription, except if such person already maintains an active 102
pharmacy license; 103
[(18)] (20) "Medication reconciliation" means a process of comparing 104
the medications a patient is taking and should be taking with newly 105
ordered medications: (A) [for] For the purpose of addressing 106
duplications, omissions and interactions and the need to continue 107
current medications; [,] and (B) by looking at information such as the 108
medication name, dose, frequency, route of administration and 109
purpose; 110 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
5 of 29
[(19)] (21) "Nonlegend device" means a device that is not a legend 111
device; 112
[(20)] (22) "Nonlegend drug" means a drug that is not a legend drug; 113
(23) "Nonresident pharmacy" has the same meaning as provided in 114
section 20-627; 115
[(21)] (24) "Person" means an individual, corporation, business trust, 116
estate trust, partnership, association, joint venture or any other legal or 117
commercial entity; 118
[(22)] (25) "Pharmacist" means an individual who is licensed to 119
practice pharmacy under the provisions of section 20-590, 20-591, 20-120
592 or 20-593, and who is thereby recognized as a health care provider 121
by the state of Connecticut; 122
[(23)] (26) "Pharmacy" means a place of business where drugs and 123
devices may be sold at retail and for which a pharmacy license has 124
been issued to an applicant under the provisions of section 20-594, as 125
amended by this act; 126
[(24)] (27) "Pharmacy intern" means an individual registered under 127
the provisions of section 20-598; 128
[(25)] (28) "Pharmacy technician" means an individual who is 129
registered with the department and qualified in accordance with 130
section 20-598a; 131
[(26)] (29) "Polypharmacy" means the use of multiple drugs by a 132
patient, including any medication that is inappropriate or not 133
medically necessary, such as those not indicated, not effective or 134
constituting a therapeutic duplication; 135
[(27)] (30) "Practice of pharmacy" or "to practice pharmacy" means 136
the sum total of knowledge, understanding, judgments, procedures, 137
securities, controls and ethics used by a pharmacist to assure optimal 138 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
6 of 29
safety and accuracy in the distributing, dispensing and use of drugs 139
and devices; 140
[(28)] (31) "Prescribing practitioner" means an individual licensed by 141
the state of Connecticut, any other state of the United States, the 142
District of Columbia, the Commonwealth of Puerto Rico or any 143
territory or insular possession subject to the jurisdiction of the United 144
States who is authorized to issue a prescription within the scope of the 145
individual's practice; 146
[(29)] (32) "Prescription" means a lawful order of a prescribing 147
practitioner transmitted either orally, in writing or by electronic means 148
for a drug or device for a specific patient; 149
[(30)] (33) "Sale" includes barter, exchange or gift or offer and each 150
such transaction made by a person whether as principal proprietor, 151
agent, servant or employee; 152
[(31)] (34) "Substitute" means to dispense without the prescribing 153
practitioner's express authorization a different drug product than the 154
drug product prescribed; 155
[(32)] (35) "Third-party logistics provider" means a person who 156
distributes drugs, devices or cosmetics while taking possession of the 157
drugs, devices or cosmetics but who does not take title of the drugs, 158
devices or cosmetics; 159
[(33)] (36) "Virtual manufacturer" means a person who engages in 160
the manufacture of drugs, devices or cosmetics for which such person: 161
(A) Owns the new drug application or abbreviated new drug 162
application number, if a prescription drug; (B) owns the unique device 163
identification number, as available, for a prescription device; (C) 164
contracts with a contract manufacturing organization for the physical 165
manufacture of the drugs, devices or cosmetics; (D) is not involved in 166
the physical manufacture of the drugs, devices or cosmetics; and (E) at 167
no time takes physical possession of or stores the drugs, devices or 168
cosmetics; and 169 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
7 of 29
[(34)] (37) "Virtual wholesale distributor" means a person who 170
facilitates or brokers the transfer of drugs, devices or cosmetics 171
without taking physical possession of the drugs, devices or cosmetics. 172
Sec. 2. (NEW) (Effective July 1, 2023) (a) For the purposes of this 173
section: 174
(1) "COVID-19" means the respiratory disease designated by the 175
World Health Organization on February 11, 2020, as coronavirus 2019, 176
and any related mutation thereof recognized by said organization; 177
(2) "COVID-19-related test" means any laboratory test, or series of 178
laboratory tests, for any virus, antibody, antigen or etiologic agent 179
thought to cause, or indicate the presence of, COVID-19; 180
(3) "HIV-related prophylaxis" means any drug approved by the 181
federal Food and Drug Administration or any successor agency as a 182
pre-exposure or post-exposure prophylaxis for the human 183
immunodeficiency virus; 184
(4) "HIV-related test" has the same meaning as provided in section 185
19a-7o of the general statutes; and 186
(5) "Influenza-related test" means any laboratory test, or series of 187
laboratory tests, for any virus, antibody, antigen or etiologic agent 188
thought to cause, or indicate the presence of, influenza disease. 189
(b) (1) Any person who is licensed as a pharmacist under chapter 190
400j of the general statutes and employed by: (A) A pharmacy that has 191
submitted to the Department of Public Health a complete clinical 192
laboratory improvement amendment application for certification for a 193
COVID-19-related test, HIV-related test or influenza-related test may 194
order, and administer to a patient, the COVID-19-related test, HIV-195
related test or influenza-related test if the patient is (i) eighteen years 196
of age or older, or (ii) at least twelve years of age but younger than 197
eighteen years of age with (I) the consent of such patient's parent, legal 198
guardian or other person having legal custody of such patient, or (II) 199 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
8 of 29
proof that such patient is an emancipated minor; or (B) a hospital may 200
order, and administer to a patient, a COVID-19-related test, HIV-201
related test or influenza-related test if the patient is (i) eighteen years 202
of age or older, or (ii) at least twelve years of age but younger than 203
eighteen years of age with (I) the consent of such patient's parent, legal 204
guardian or other person having legal custody of such patient, or (II) 205
proof that such patient is an emancipated minor. 206
(2) If a pharmacist orders and administers a COVID-19-related test, 207
HIV-related test or influenza-related test under subdivision (1) of this 208
subsection, the pharmacist shall: (A) Provide to the patient, in writing, 209
the results of such test; (B) maintain a record of the results of such test 210
for a period of three years; and (C) provide to the Commissioner of 211
Consumer Protection or the commissioner's designee, upon a request 212
made by the commissioner or the commissioner's designee, a copy of 213
the results of such test. 214
(c) (1) If a pharmacist orders and administers any HIV-related test 215
under subdivision (1) of subsection (b) of this section and the result of 216
such test is negative, the pharmacist may prescribe and dispense to the 217
patient any HIV-related prophylaxis according to the manufacturer's 218
package insert, provided: (A) Such patient satisfies the criteria 219
established in such package insert; and (B) such HIV -related 220
prophylaxis is prescribed and dispensed in accordance with all 221
applicable requirements established in chapter 400j of the general 222
statutes. 223
(2) If a pharmacist prescribes any HIV-related prophylaxis under 224
subdivision (1) of this subsection, the pharmacist shall provide to the 225
Commissioner of Consumer Protection or the commissioner's 226
designee, upon a request made by the comm issioner or the 227
commissioner's designee: (A) A copy of the results of the HIV-related 228
test; (B) prescription information maintained pursuant to chapter 400j 229
of the general statutes; and (C) any other documentation the 230
commissioner requires in regulations adopted pursuant to subsection 231
(d) of this section. 232 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
9 of 29
(d) The Commissioner of Consumer Protection, in consultation with 233
the Commissioner of Public Health and the Commission of Pharmacy, 234
shall adopt regulations, in accordance with chapter 54 of the general 235
statutes, to implement the provisions of this section. Such regulations 236
shall, at a minimum: (1) Identify qualifying training programs, which 237
are accredited by the National Centers for Disease Control and 238
Prevention, the Accreditation Council for Pharmacy Education or 239
another appropriate national accrediting body; and (2) establish a 240
system of control and reporting. 241
Sec. 3. (NEW) (Effective July 1, 2023) (a) (1) A pharmacy may apply to 242
the department, in a form and manner prescribed by the 243
commissioner, to operate a mobile pharmacy in a temporary location 244
for the purpose of: (A) Conducting (i) a temporary clinic, (ii) a 245
vaccination event, or (iii) an opioid antagonist training and prescribing 246
event; or (B) serving a community that may not have adequate access 247
to pharmacy services. 248
(2) No pharmacy may operate a mobile pharmacy without prior 249
written approval from the department. Each mobile pharmacy shall be 250
supervised by a pharmacist. The department may inspect a mobile 251
pharmacy before pharmacy services are provided in the mobile 252
pharmacy, and at any time during usual business hours or while such 253
mobile pharmacy is in operation. The department may issue an order 254
closing a mobile pharmacy if the department determines that: (A) The 255
mobile pharmacy has failed to comply with the provisions of this 256
section; (B) conditions are unsafe to store or dispense drugs; or (C) 257
there is insufficient security at such mobile pharmacy. 258
(b) A pharmacy that operates a mobile pharmacy under this section 259
shall: (1) Maintain a record of all drugs that are removed from the 260
pharmacy premises for the purpose of operating such mobile 261
pharmacy; (2) maintain a record of each drug that is dispensed at such 262
mobile pharmacy and include such record in such pharmacy's records 263
not later than twenty-four hours after such drug is dispensed; (3) 264
except as provided in subsection (c) of this section, inventory and 265 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
10 of 29
return all unused drugs to the pharmacy premises by the close of 266
business each day; (4) while operating such mobile pharmacy, store all 267
drugs in such mobile pharmacy in a manner that (A) prevents any 268
drug diversion, and (B) is consistent with the storage conditions 269
specified by the manufacturers of such drugs; (5) establish and 270
maintain a patient communication plan to ensure that patients can 271
obtain prescription refills if such mobile pharmacy is unavailable; and 272
(6) if permitted by the federal Drug Enforcement Administration or a 273
successor agency, store controlled substances in the mobile pharmacy 274
in accordance with regulations adopted by the commissioner pursuant 275
to section 21a-262 of the general statutes. 276
(c) No pharmacy shall, without prior approval from the department: 277
(1) Operate a mobile pharmacy for more than (A) seven consecutive 278
days in a single location, or (B) fourteen days within a five-mile radius 279
of the prior mobile pharmacy location; or (2) store drugs overnight in a 280
mobile pharmacy or outside of the pharmacy premises. 281
(d) The commissioner may, with the advice and consent of the 282
commission, adopt regulations in accordance with chapter 54 of the 283
general statutes to implement the provisions of this section. 284
Sec. 4. (NEW) (Effective July 1, 2023) (a) For the purposes of this 285
section, "pharmacy district manager" means an individual who (1) 286
supervises at least three pharmacies within this state, and (2) is 287
responsible for the activities within such pharmacies, including, but 288
not limited to, staffing, payroll and hiring. 289
(b) Each pharmacy shall maintain a plan to manage unscheduled 290
closings. Such plan shall be reviewed and updated, if necessary, on an 291
annual basis, and be provided to, and reviewed with, all pharmacy 292
personnel on an annual basis. Such plan shall include: 293
(1) The name of the individual who is responsible for notifying the 294
Commission of Pharmacy of an unscheduled closing; 295
(2) The name of the individual who is responsible for updating the 296 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
11 of 29
hours of operation in the pharmacy's electronic record system to 297
prevent acceptance of electronically transmitted prescriptions during 298
an unscheduled closing; 299
(3) The name of the individual who is responsible for updating the 300
pharmacy's telephone system during an unscheduled closing to (A) 301
prevent the acceptance of orally transmitted prescriptions during the 302
unscheduled closing, and (B) provide a message that alerts patients 303
that such pharmacy will be closed and their prescriptions may be 304
obtained from a nearby pharmacy; 305
(4) A list of all pharmacies that are located within a two-mile radius 306
of the pharmacy that is experiencing an unscheduled closing, or the 307
next closest pharmacy if there is no pharmacy within such two-mile 308
radius; and 309
(5) The name of the individual who is responsible for posting, at the 310
entrance to such pharmacy and at each entrance of the structure if such 311
pharmacy is located within another structure, signage stating the 312
duration of an unscheduled closing. 313
(c) If a pharmacy experiences an unscheduled closing, the 314
pharmacist manager of the pharmacy or, if the pharmacy operates 315
more than five pharmacy locations in this state, the pharmacy district 316
manager shall: 317
(1) Modify such pharmacy's hours of operation in such pharmacy's 318
electronic record system to prevent the acceptance of electronically 319
transmitted prescriptions during the unscheduled closing; 320
(2) Adjust such pharmacy's telephone system to prevent the 321
acceptance of orally transmitted prescriptions during the unscheduled 322
closing; 323
(3) Provide a telephone system message alert to patients notifying 324
patients that (A) such pharmacy is not open, and (B) patients may 325
obtain medications from a nearby pharmacy; 326 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
12 of 29
(4) Post signage at the entrance to such pharmacy, and at each 327
entrance of the structure if such pharmacy is located within another 328
structure, (A) stating that such pharmacy is closed, (B) disclosing the 329
duration of the unscheduled closing, and (C) providing (i) a list of all 330
pharmacies that are located within a two-mile radius of such 331
pharmacy, or (ii) the next closest pharmacy if there is no pharmacy 332
within such two-mile radius; and 333
(5) Upon request by another pharmacy to transfer a prescription to 334
such other pharmacy, transfer any prescription dispensed by the 335
pharmacy experiencing the unscheduled closing and reverse any third-336
party payor claims associated with such prescription. 337
(d) Any pharmacy that verifies that another pharmacy is 338
experiencing an unscheduled closing may, upon a patient's request, 339
dispense a prescription that is dispensed and waiting at the pharmacy 340
experiencing the unscheduled closing by using information obtained 341
from the closed pharmacy, the electronic prescription drug monitoring 342
program or another source that the pharmacist dispensing such 343
prescription believes provides a reasonable assurance of accurate 344
information necessary to dispense such prescription. In the event that a 345
pharmacy dispenses a prescription during an unscheduled closing of 346
another pharmacy: 347
(1) The pharmacy dispensing such prescription shall contact the 348
pharmacy experiencing the unscheduled closing not later than twenty-349
four hours after such closed pharmacy reopens to transfer such 350
prescription, in accordance with section 20-616 of the general statutes; 351
(2) The pharmacy that experienced the unscheduled closing shall 352
provide to the pharmacy that dispensed such prescription during such 353
unscheduled closing all information necessary for the transfer of such 354
prescription; and 355
(3) The pharmacy that experienced the unscheduled closing shall 356
reverse any third-party payor claims associated with such transferred 357 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
13 of 29
prescription not later than twenty-four hours after such pharmacy 358
reopens. 359
(e) The Department of Consumer Protection shall adopt regulations, 360
in accordance with chapter 54 of the general statutes, to implement the 361
provisions of this section. Such regulations shall include, but need not 362
be limited to, provisions for the placement of a secured container at a 363
pharmacy that allows patients to, during the hours in which the 364
pharmacy may be open or closed, obtain prescriptions that were 365
dispensed by such pharmacy. Prior to the effective date of such 366
regulations, the department may temporarily permit the use and 367
placement of a secured container at a pharmacy, provided the 368
pharmacy submits to the department, for the department's approval, 369
written protocols prior to placing, providing access to or using the 370
secured container and such pharmacy receives written approval from 371
the department for such placement, access or use. To obtain temporary 372
approval under this subsection, a secure container shall: 373
(1) Weigh more than seven hundred fifty pounds or be affixed to the 374
physical structure of the building where the pharmacy is located, and 375
be located immediately adjacent to the portion of such building where 376
such pharmacy is located; 377
(2) Only permit access to authorized pharmacy personnel or 378
individuals retrieving the prescriptions with a unique identification 379
system; 380
(3) Be under video surveillance at all times; 381
(4) Be capable of maintaining a record of all products that are placed 382
inside of the secure container, and the date and time each individual 383
prescription is accessed; and 384
(5) Comply with any other protocol required by the department to 385
ensure patient confidentiality, ensure public health and safety and 386
prevent diversion. 387 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
14 of 29
Sec. 5. Section 20-633 of the general statutes is repealed and the 388
following is substituted in lieu thereof (Effective July 1, 2023): 389
(a) (1) Any person licensed as a pharmacist under part II of this 390
chapter may [(1)] administer: [, to an adult, any] 391
(A) Any vaccine, approved or authorized by the United States Food 392
and Drug Administration that is listed on the National Centers for 393
Disease Control and Prevention's Adult Immunization Schedule, [and 394
(2) on and after July 1, 2022, administer to any person between the ages 395
of twelve and seventeen, with the consent of such person's parent or 396
guardian, the influenza vaccine approved by the United States Food 397
and Drug Administration, provided the administration of any vaccine 398
under this subsection is conducted pursuant to the order of a licensed 399
health care provider and in accordance with the regulations 400
established pursuant to subsection (b) of this section.] to any patient 401
who is: (i) Eighteen years of age or older; or (ii) at least twelve years of 402
age but younger than eighteen years of age with (I) the consent of such 403
patient's parent, legal guardian or other person having legal custody of 404
such patient, or (II) proof that such patient is an emancipated minor. 405
(B) Any vaccine not included on the National Centers for Disease 406
Control and Prevention's Adult Immunization Schedule, provided the 407
vaccine administration instructions for such vaccine are available on 408
the National Centers for Disease Control and Prevention's Internet web 409
site; and 410
(C) Any vaccine pursuant to a verbal or written prescription of a 411
prescribing practitioner for a specific patient. 412
(2) A pharmacist shall make a reasonable effort to review a patient's 413
vaccination history to prevent any inappropriate use of a requested 414
vaccine. 415
(3) All vaccines administered pursuant to this section shall be 416
administered in accordance with the: (A) Vaccine manufacturer's 417
package insert or the orders of a prescribing practitioner; and (B) 418 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
15 of 29
regulations adopted pursuant to subsection (c) of this section. 419
(b) A pharmacist who has completed the training required in 420
regulations adopted pursuant to subsection (c) of this section may 421
administer an epinephrine cartridge injector, as defined in section 19a-422
909, to a patient whom the pharmacist reasonably believes, based on 423
such pharmacist's knowledge and training, is experiencing 424
anaphylaxis, regardless of whether such patient has a prescription for 425
an epinephrine cartridge injector. Such pharmacist, or such 426
pharmacist's designee, shall call the 9-1-1 emergency telephone 427
number either before or immediately after suc h pharmacist 428
administers the epinephrine cartridge injector to such patient. Such 429
pharmacist shall document the date, time and circumstances in which 430
such pharmacist administered such epinephrine cartridge injector, and 431
maintain such documentation for at least three years. 432
[(b)] (c) The Commissioner of Consumer Protection, in consultation 433
with the Commissioner of Public Health and the Commission of 434
Pharmacy, shall adopt regulations, in accordance with the provisions 435
of chapter 54, to implement the provisions of this section. Such 436
regulations shall: (1) [require] Require any pharmacist who 437
administers a vaccine pursuant to this section to successfully complete 438
an immunization training program for pharmacists; (2) define the basic 439
requirements of such training program, which shall include training 440
and instruction in pre-administration education and screening, vaccine 441
storage and handling, subcutaneous and intramuscular injections, 442
recordkeeping, vaccine safety, cardiopulmonary resuscitation, basic 443
cardiac life support and adverse event reporting; (3) identify 444
qualifying training programs, which are accredited by the National 445
Centers for Disease Control Prevention, the Accreditation Council for 446
Pharmacy Education or [other] another appropriate national 447
accrediting body; and (4) establish a system of control and reporting. 448
[(c) For purposes of this section, "adult" means a person who has 449
attained the age of eighteen years.] 450 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
16 of 29
Sec. 6. Subsection (a) of section 20-576 of the general statutes is 451
repealed and the following is substituted in lieu thereof (Effective July 452
1, 2023): 453
(a) The commissioner may, with the advice and assistance of the 454
commission, adopt regulations, in accordance with chapter 54, to 455
govern the performance of the commission's duties, the practice of 456
pharmacy and the business of retailing drugs and devices. Such 457
regulations may include, but are not limited to, provisions (1) 458
concerning the licensing of any pharmacist or pharmacy, disciplinary 459
action that may be taken against a licensee, the conduct of a 460
pharmacist and the operation of a pharmacy, (2) specifying various 461
classes of pharmacy licenses issued under section 20-594, as amended 462
by this act, including, but not limited to, licenses for infusion therapy 463
pharmacies, [and] nuclear pharmacies and health care institutional 464
pharmacies, and specifying requirements for operation of pharmacies 465
under the classes of pharmacy licenses permitted under the 466
regulations, (3) concerning creation and maintenance of prescription 467
records, and (4) concerning registration and activities of pharmacy 468
interns, registered pharmacy technicians and certified pharmacy 469
technicians. 470
Sec. 7. Section 20-594 of the general statutes is repealed and the 471
following is substituted in lieu thereof (Effective July 1, 2023): 472
(a) Except as limited by section 20-596, a pharmacist, health care 473
institution or any other person may apply to the commission for a 474
pharmacy license or for renewal of a pharmacy license. 475
(b) The applicant shall disclose on the application the name and 476
address of the applicant and the owner of the pharmacy, the name and 477
street and mailing address of the pharmacy and the name, address and 478
license number of the pharmacist who manages the pharmacy. The 479
commissioner may, by regulation adopted with the advice and 480
assistance of the commission, in accordance with chapter 54, require 481
such other information on the application as is necessary for the 482 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
17 of 29
department to carry out [its] the department's duties under sections 20-483
570 to 20-630, inclusive. 484
(c) The department shall, after receipt of an application under this 485
section, (1) issue, on authorization of the commission, a pharmacy 486
license to an applicant for a new pharmacy on payment of the fee 487
required in section 20-601 and on satisfactory evidence to the 488
commission that the pharmacy will be managed by a pharmacist and 489
will be operated in accordance with the general statutes and the 490
regulations adopted by the commissioner in accordance with chapter 491
54, and (2) issue a renewal of a pharmacy license to an applicant on 492
payment of the fee required in section 20-601. 493
(d) Pharmacy licenses shall expire annually. Pharmacy licenses may 494
be renewed on application and payment of the fee required in section 495
20-601 for a period not to exceed one year. 496
(e) When a pharmacy is transferred to a new location the pharmacy 497
license for such pharmacy shall terminate. A pharmacy license that has 498
been terminated under this subsection may be renewed under the 499
provisions of subsection (d) of this section and on satisfactory evidence 500
to the commission that the pharmacy will be managed by a pharmacist 501
and will be operated in accordance with the general statutes and the 502
regulations adopted by the commissioner in accordance with chapter 503
54. 504
(f) Each pharmacy licensed pursuant to this section shall report to 505
the department any administrative or legal action commenced against 506
[it] such pharmacy by any state or federal regulatory agency or 507
accreditation entity not later than ten business days after receiving 508
notice of the commencement of such action. 509
Sec. 8. Section 20-633b of the general statutes is repealed and the 510
following is substituted in lieu thereof (Effective July 1, 2023): 511
(a) As used in this section: 512 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
18 of 29
(1) "Medical order" means a written, oral or electronic order by a 513
prescribing practitioner [, as defined in section 20-14c,] for a drug to be 514
dispensed by a pharmacy for administration to a patient; 515
(2) "Prescribing practitioner" has the same meaning as provided in 516
section 20-14c; 517
[(2)] (3) "Sterile compounding pharmacy" means a pharmacy [, as 518
defined in section 20-571, a] or nonresident pharmacy [registered 519
pursuant to section 20-627,] that dispenses or compounds sterile 520
pharmaceuticals; 521
[(3)] (4) "Sterile pharmaceutical" means any dosage form of a drug, 522
including, but not limited to, parenterals, injectables, surgical irrigants 523
and ophthalmics devoid of viable microorganisms; and 524
[(4)] (5) "USP chapters" means chapters 797, 800 and 825 of the 525
United States Pharmacopeia that pertain to compounding sterile 526
pharmaceuticals and their referenced companion documents, as 527
amended from time to time. 528
(b) (1) (A) If an applicant for a new pharmacy license [pursuant to] 529
under section 20-594, as amended by this act, intends to compound 530
sterile pharmaceuticals, the applicant shall file an addendum to [its] 531
the pharmacy license application such applicant files pursuant to 532
section 20-594, as amended by this act, to include sterile 533
pharmaceutical compounding. The [Department of Consumer 534
Protection] department shall inspect the proposed pharmacy premises 535
of [the] such applicant and [the] such applicant shall not compound 536
sterile pharmaceuticals until [it] such applicant receives notice that the 537
addendum to such applicant's application has been approved by the 538
department and the [Commission of Pharmacy] commission. Nothing 539
in this section shall be construed to affect a licensed hospital's ability to 540
compound sterile pharmaceuticals for such hospital's patients 541
consistent with federal law. 542
[(2)] (B) If an existing pharmacy licensed pursuant to section 20-594, 543 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
19 of 29
as amended by this act, intends to compound sterile pharmaceuticals 544
for the first time on or after July 1, 2014, such pharmacy shall [file an] 545
apply for an addendum [application to its] to such pharmacy's 546
application on file with the department to include sterile 547
pharmaceutical compounding. The [Department of Consumer 548
Protection] department shall inspect the pharmacy premises of such 549
pharmacy and [the] such pharmacy shall not compound sterile 550
pharmaceuticals until [it] such pharmacy receives written notice that 551
such addendum application has been approved by the department and 552
the [Commission of Pharmacy] commission. 553
(C) If an existing health care institutional pharmacy licensed 554
pursuant to section 20-594, as amended by this act, intends to 555
compound sterile pharmaceuticals for the first time on or after July 1, 556
2023, such health care institutional pharmacy shall apply for an 557
addendum to such health care institutional pharmacy's application on 558
file with the department to include sterile pharmaceutical 559
compounding. The department shall inspect the pharmacy premises of 560
such health care institutional pharmacy, and such health care 561
institutional pharmacy shall not compound sterile pharmaceuticals 562
until such health care institutional pharmacy receives written notice 563
that such health care institutional pharmacy's addendum application 564
has been approved by the department and the commission. 565
[(3)] (2) (A) If an applicant for a new nonresident pharmacy 566
registration intends to compound sterile pharmaceuticals for sale or 567
delivery in this state, the applicant shall file an addendum to [its] the 568
registration application such applicant files pursuant to section 20-627 569
to include sterile pharmaceutical compounding. [The] Such applicant 570
shall provide to the department [with] written proof [it] that such 571
applicant has passed inspection by the appropriate state agency in the 572
state where such [nonresident pharmacy] applicant is located. Such 573
[pharmacy] applicant shall not compound sterile pharmaceuticals for 574
sale or delivery in this state until [it] such applicant receives written 575
notice that [the] such addendum [application] has been approved by 576 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
20 of 29
the department and the [Commission of Pharmacy] commission. 577
[(4)] (B) If [a] an existing nonresident pharmacy [registered 578
pursuant to section 20-627] intends to compound sterile 579
pharmaceuticals for sale or delivery in this state for the first time on or 580
after July 1, 2014, [the] such nonresident pharmacy shall [file] apply for 581
an addendum to [its] such nonresident pharmacy's application on file 582
with the department to include sterile pharmaceutical compounding. 583
[The] Such nonresident pharmacy shall provide to the department 584
[with] written proof [it] that such nonresident pharmacy has passed 585
inspection by the appropriate state agency in the state where such 586
nonresident pharmacy is located. Such nonresident pharmacy shall not 587
compound sterile pharmaceuticals until [it] such nonresident 588
pharmacy receives written notice that [the] such addendum 589
application has been approved by the department and the 590
[Commission of Pharmacy] commission. 591
(c) A sterile compounding pharmacy shall comply with the USP 592
chapters. A sterile compounding pharmacy shall also comply with all 593
applicable federal and state statutes and regulations. 594
[(d) An institutional pharmacy within a facility licensed pursuant to 595
section 19a-490 that compounds sterile pharmaceuticals shall comply 596
with the USP chapters, and shall also comply with all applicable 597
federal and state statutes and regulations. Such institutional pharmacy 598
may request from the Commissioner of Consumer Protection an 599
extension of time, not to exceed six months, to comply, for state 600
enforcement purposes, with any amendments to USP chapters, for 601
good cause shown. The commissioner may grant an extension for a 602
length of time not to exceed six months. Nothing in this section shall 603
prevent such institutional pharmacy from requesting a subsequent 604
extension of time or shall prevent the commissioner from granting 605
such extension.] 606
[(e)] (d) (1) A sterile compounding pharmacy may only provide 607
patient-specific sterile pharmaceuticals to patients, to practitioners of 608 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
21 of 29
medicine, osteopathy, podiatry, dentistry or veterinary medicine, or to 609
an acute care or long-term care hospital or health care facility licensed 610
by the Department of Public Health. 611
(2) If a sterile compounding pharmacy provides sterile 612
pharmaceuticals without a patient-specific prescription or medical 613
order, the sterile compounding pharmacy shall also obtain a certificate 614
of registration from the Department of Consumer Protection pursuant 615
to section 21a-70, as amended by this act, and any required federal 616
license or registration. A sterile compounding pharmacy may prepare 617
and maintain on-site inventory of sterile pharmaceuticals no greater 618
than a thirty-day supply, calculated from the completion of 619
compounding, which thirty-day period shall include the period 620
required for third-party analytical testing, to be performed in 621
accordance with the USP chapters. 622
[(f)] (e) (1) If a sterile compounding pharmacy plans to remodel any 623
area utilized for the compounding of sterile pharmaceuticals or 624
adjacent space, relocate any space utilized for the compounding of 625
sterile pharmaceuticals or upgrade or conduct a nonemergency repair 626
to the heating, ventilation, air conditioning or primary or secondary 627
engineering controls for any space utilized for the compounding of 628
sterile pharmaceuticals, the sterile compounding pharmacy shall notify 629
the Department of Consumer Protection, in writing, not later than 630
forty-five days prior to commencing such remodel, relocation, upgrade 631
or repair. Such written notification shall include a plan for such 632
remodel, relocation, upgrade or repair and such plan shall be subject to 633
department review and approval. If a sterile compounding pharmacy 634
makes an emergency repair, the sterile compounding pharmacy shall 635
notify the department of such emergency repair, in writing, not later 636
than twenty-four hours after such repair is commenced. 637
(2) If the USP chapters require sterile recertification after such 638
remodel, relocation, upgrade or repair, the sterile compounding 639
pharmacy shall provide a copy of [its] such sterile compounding 640
pharmacy's sterile recertification to the Department of Consumer 641 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
22 of 29
Protection not later than five days after the sterile recertification 642
approval. The recertification shall only be performed by an 643
independent licensed environmental monitoring entity. 644
[(g)] (f) A sterile compounding pharmacy shall report, in writing, to 645
the Department of Consumer Protection any known violation or 646
noncompliance with viable and nonviable environmental sampling 647
testing, as defined in the USP chapters, not later than the end of the 648
next business day after discovering such violation or noncompliance. 649
[(h)] (g) (1) If a sterile compounding pharmacy initiates a recall of 650
sterile pharmaceuticals that were dispensed pursuant to a patient-651
specific prescription or medical order, the sterile compounding 652
pharmacy shall notify each patient or patient care giver, the 653
prescribing practitioner and the Department of Consumer Protection 654
of such recall not later than twenty-four hours after such recall was 655
initiated. 656
(2) If a sterile compounding pharmacy initiates a recall of sterile 657
pharmaceuticals that were not dispensed pursuant to a patient-specific 658
prescription or a medical order, the sterile compounding pharmacy 659
shall notify: (A) Each purchaser of such sterile pharmaceuticals, to the 660
extent such sterile compounding pharmacy possesses contact 661
information for each such purchaser, (B) the Department of Consumer 662
Protection, and (C) the federal Food and Drug Administration of such 663
recall not later than the end of the next business day after such recall 664
was initiated. 665
[(i)] (h) Each sterile compounding pharmacy [and each institutional 666
pharmacy within a facility licensed pursuant to section 19a-490] shall 667
prepare and maintain a policy and procedure manual. The policy and 668
procedure manual shall comply with the USP chapters. 669
[(j)] (i) Each sterile compounding pharmacy shall report to the 670
Department of Consumer Protection any administrative or legal action 671
commenced against [it] such sterile compounding pharmacy by any 672 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
23 of 29
state or federal regulatory agency or accreditation entity not later than 673
five business days after receiving notice of the commencement of such 674
action. 675
[(k)] (j) Notwithstanding the provisions of [subdivisions (3) and (4)] 676
subdivision (2) of subsection (b) of this section, a sterile compounding 677
pharmacy that is a nonresident pharmacy shall provide to the 678
Department of Consumer Protection proof that [it] such nonresident 679
pharmacy has passed an inspection in such nonresident pharmacy's 680
home state, based on the USP chapters. Such nonresident pharmacy 681
shall submit to the Department of Consumer Protection a copy of the 682
most recent inspection report with [its] such nonresident pharmacy's 683
initial nonresident pharmacy application and shall submit to the 684
department a copy of [its] such nonresident pharmacy's most recent 685
inspection report every two years thereafter. If the state in which [the] 686
such nonresident pharmacy is located does not conduct inspections 687
based on standards required in the USP chapters, such nonresident 688
pharmacy shall provide satisfactory proof to the department that [it] 689
such nonresident pharmacy is in compliance with the standards 690
required in the USP chapters. 691
[(l)] (k) A practitioner, as specified in subdivision (1) of subsection 692
[(e)] (d) of this section, a hospital or a health care facility that receives 693
sterile pharmaceuticals shall report any errors related to such 694
dispensing or any suspected adulterated sterile pharmaceuticals to the 695
Department of Consumer Protection. 696
[(m)] (l) (1) For purposes of this subsection, a "designated 697
pharmacist" means a pharmacist responsible for overseeing the 698
compounding of sterile pharmaceuticals and the application of the 699
USP chapters, as said chapters pertain to sterile compounding. 700
(2) Any pharmacy licensed pursuant to section 20-594, as amended 701
by this act, [or institutional pharmacy licensed pursuant to section 19a-702
490] that provides sterile pharmaceuticals shall notify the department 703
of [its] such pharmacy's designated pharmacist. 704 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
24 of 29
(3) The designated pharmacist shall be responsible for providing 705
proof [he or she] such designated pharmacist has completed a program 706
approved by the commissioner that demonstrates the competence 707
necessary for the compounding of sterile pharmaceuticals, in 708
compliance with all applicable federal and state statutes and 709
regulations. 710
(4) The designated pharmacist shall immediately notify the 711
department whenever [he or she] such designated pharmacist ceases 712
such designation. 713
(5) Nothing in this section shall prevent a designated pharmacist 714
from being the pharmacy manager. 715
[(n)] (m) The Commissioner of Consumer Protection may adopt 716
regulations, in accordance with chapter 54, to implement the 717
provisions of this section. 718
Sec. 9. Subsections (a) and (b) of section 21a-65 of the general 719
statutes are repealed and the following is substituted in lieu thereof 720
(Effective July 1, 2023): 721
(a) A licensed manufacturer or licensed wholesaler may sell 722
hypodermic needles and syringes only to the following: (1) To a 723
licensed manufacturer, licensed wholesaler or licensed pharmacy; (2) 724
to a physician, dentist, veterinarian, embalmer, podiatrist or scientific 725
investigator licensed to practice in this state; (3) to a person in charge 726
of a care-giving institution, as defined in [subdivision (3) of] section 20-727
571, as amended by this act, incorporated college or scientific 728
institution, but only for use by or in such care-giving institution, 729
college or institution for medical or scientific purposes; (4) to a person 730
in charge of a licensed or registered laboratory, but only for use in that 731
laboratory for scientific and medical purposes; (5) to a farmer but only 732
for use on the farmer's own animals or poultry; (6) to a business 733
authorized in accordance with the regulations adopted under section 734
21a-66 to purchase hypodermic needles and syringes but only for 735 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
25 of 29
legitimate industrial or medical use within that business; and (7) to a 736
syringe services program established pursuant to section 19a-124. 737
(b) Except as provided in subsection (a) of this section, no licensed 738
manufacturer, licensed wholesaler or licensed pharmacist shall sell and 739
no person shall buy a hypodermic needle or syringe except upon a 740
prescription of a prescribing practitioner, as defined in [subdivision 741
(28) of] section 20-571, as amended by this act, in a quantity greater 742
than ten. Any such prescription shall be retained on file by the seller 743
for a period of not less than three years and shall be accessible to any 744
public officer engaged in the enforcement of this section. Such a 745
prescription shall be valid for one year from the date thereof and 746
purchases and sales may be made thereunder during such period, 747
provided the seller shall confirm the continued need for such sales 748
with such practitioner at least every six months if sales continue to be 749
made thereunder. Hypodermic needles and syringes in a quantity of 750
ten or less without a prescription may be provided or sold at retail 751
only by the following: (1) By a pharmacy licensed in accordance with 752
section 20-594, as amended by this act, and in such pharmacy only by a 753
licensed pharmacist or under the pharmacist's direct supervision; (2) 754
by a syringe service program established pursuant to section 19a-124; 755
and (3) by a health care facility or a licensed health care practitioner for 756
use by their own patients. 757
Sec. 10. Subsection (a) of section 21a-70 of the general statutes is 758
repealed and the following is substituted in lieu thereof (Effective July 759
1, 2023): 760
(a) As used in this section: (1) "Drugs", "devices" and "cosmetics" 761
have the same meanings as defined in section 21a-92, "wholesaler" or 762
"distributor" means a person, including, but not limited to, a medical 763
device and oxygen provider, a third-party logistics provider, a virtual 764
manufacturer or a virtual wholesale distributor, as such terms are 765
defined in section 20-571, as amended by this act, whether within or 766
without the boundaries of the state of Connecticut, who supplies 767
drugs, devices or cosmetics prepared, produced or packaged by 768 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
26 of 29
manufacturers, to other wholesalers, manufacturers, distributors, 769
hospitals, prescribing practitioners, as defined in [subdivision (28) of] 770
section 20-571, as amended by this act, pharmacies, federal, state or 771
municipal agencies, clinics or any other person as permitted under 772
subsection (h) of this section, except that: (A) A retail pharmacy or a 773
pharmacy within a licensed hospital that supplies to another such 774
pharmacy a quantity of a noncontrolled drug or a schedule II, III, IV or 775
V controlled substance normally stocked by such pharmacies to 776
provide for the immediate needs of a patient pursuant to a prescription 777
or medication order of an authorized practitioner, (B) a pharmacy 778
within a licensed hospital that supplies drugs to another hospital or an 779
authorized practitioner for research purposes, (C) a retail pharmacy 780
that supplies a limited quantity of a noncontrolled drug or of a 781
schedule II, III, IV or V controlled substance for emergency stock to a 782
practitioner who is a medical director of a chronic and convalescent 783
nursing home, of a rest home with nursing supervision, of a hospice 784
inpatient facility licensed pursuant to section 19a-491 or of a state 785
correctional institution, and (D) a pharmacy within a licensed hospital 786
that contains another hospital wholly within [its] such licensed 787
hospital's physical structure that supplies to such contained hospital a 788
quantity of a noncontrolled drug or a schedule II, III, IV, or V 789
controlled substance normally stocked by such hospitals to provide for 790
the needs of a patient, pursuant to a prescription or medication order 791
of an authorized practitioner, receiving inpatient care on a unit that is 792
operated by the contained hospital, or receiving outpatient care in a 793
setting operated by the contained hospital and such drug or substance 794
is administered on-site by the contained hospital, shall not be deemed 795
a wholesaler under this section; (2) "manufacturer" means (A) a person, 796
whether within or without the boundaries of the state of Connecticut, 797
who produces, prepares, cultivates, grows, propagates, compounds, 798
converts or processes, directly or indirectly, by extraction from 799
substances of natural origin or by means of chemical synthesis or by a 800
combination of extraction and chemical synthesis, or who packages, 801
repackages, labels or relabels a container under such manufacturer's 802
own or any other trademark or label any drug, device or cosmetic for 803 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
27 of 29
the purpose of selling such items, or (B) a sterile compounding 804
pharmacy, as defined in section 20-633b, as amended by this act, that 805
dispenses sterile pharmaceuticals without a prescription or a patient-806
specific medical order; (3) "drug", "device" and "cosmetic" have the 807
same meanings as provided in section 21a-92; and (4) "commissioner" 808
means the Commissioner of Consumer Protection or [his or her] the 809
commissioner's designee. 810
Sec. 11. Subsection (k) of section 21a-106 of the general statutes is 811
repealed and the following is substituted in lieu thereof (Effective July 812
1, 2023): 813
(k) If it is a legend drug, as defined in [subdivision (16) of] section 814
20-571, as amended by this act, that is not administered, dispensed, 815
prescribed or otherwise possessed or distributed in accordance with 816
federal and state laws and regulations; 817
Sec. 12. Subsection (e) of section 21a-115 of the general statutes is 818
repealed and the following is substituted in lieu thereof (Effective July 819
1, 2023): 820
(e) In the promulgation of regulations under the provisions of this 821
section applicable to prescribing practitioners, care-giving institutions, 822
and correctional and juvenile training institutions, as defined in 823
[subdivision (7) of] section 20-571, as amended by this act, the 824
Commissioner of Consumer Protection shall act in place of the 825
director. Existing regulations shall continue in effect unless superseded 826
by action of said commissioner pursuant to this subsection. 827
Sec. 13. Subsection (j) of section 21a-249 of the general statutes is 828
repealed and the following is substituted in lieu thereof (Effective July 829
1, 2023): 830
(j) A pharmacy may sell and dispense controlled substances upon 831
the prescription of a prescribing practitioner, as defined in 832
[subdivision (28) of] section 20-571, as amended by this act. 833 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
28 of 29
Sec. 14. Section 38a-492a of the general statutes is repealed and the 834
following is substituted in lieu thereof (Effective July 1, 2023): 835
Each individual health insurance policy providing coverage of the 836
type specified in subdivisions (1), (2), (4), (6), (10), (11) and (12) of 837
section 38a-469, delivered, issued for delivery, renewed, amended or 838
continued in this state shall provide coverage for hypodermic needles 839
or syringes prescribed by a prescribing practitioner, as defined in 840
[subdivision (28) of] section 20-571, as amended by this act, for the 841
purpose of administering medications for medical conditions, 842
provided such medications are covered under the policy. Such benefits 843
shall be subject to any policy provisions that apply to other services 844
covered by such policy. 845
Sec. 15. Section 38a-518a of the general statutes is repealed and the 846
following is substituted in lieu thereof (Effective July 1, 2023): 847
Each group health insurance policy providing coverage of the type 848
specified in subdivisions (1), (2), (4), (6), (10), (11) and (12) of section 849
38a-469, delivered, issued for delivery, renewed, amended or 850
continued in this state shall provide coverage for hypodermic needles 851
or syringes prescribed by a prescribing practitioner, as defined in 852
[subdivision (28) of] section 20-571, as amended by this act, for the 853
purpose of administering medications for medical conditions, 854
provided such medications are covered under the policy. Such benefits 855
shall be subject to any policy provisions that apply to other services 856
covered by such policy. 857
Sec. 16. Subdivision (1) of subsection (b) of section 53a-13 of the 858
general statutes is repealed and the following is substituted in lieu 859
thereof (Effective July 1, 2023): 860
(b) (1) It shall not be a defense under this section if such mental 861
disease or defect was proximately caused by the voluntary ingestion, 862
inhalation or injection of intoxicating liquor or any drug or substance, 863
or any combination thereof, unless such drug was prescribed for the 864 Substitute Bill No. 1102
LCO {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-01102-R01-
SB.docx }
29 of 29
defendant by a prescribing practitioner, as defined in [subdivision (28) 865
of] section 20-571, as amended by this act, and was used in accordance 866
with the directions of such prescription. 867
This act shall take effect as follows and shall amend the following
sections:
Section 1 July 1, 2023 20-571
Sec. 2 July 1, 2023 New section
Sec. 3 July 1, 2023 New section
Sec. 4 July 1, 2023 New section
Sec. 5 July 1, 2023 20-633
Sec. 6 July 1, 2023 20-576(a)
Sec. 7 July 1, 2023 20-594
Sec. 8 July 1, 2023 20-633b
Sec. 9 July 1, 2023 21a-65(a) and (b)
Sec. 10 July 1, 2023 21a-70(a)
Sec. 11 July 1, 2023 21a-106(k)
Sec. 12 July 1, 2023 21a-115(e)
Sec. 13 July 1, 2023 21a-249(j)
Sec. 14 July 1, 2023 38a-492a
Sec. 15 July 1, 2023 38a-518a
Sec. 16 July 1, 2023 53a-13(b)(1)
Statement of Legislative Commissioners:
In Section 2(b)(1), Subparas. (A) and (B) were rewritten for clarity; in
Section 2(b)(2) and (c)(1), "to a patient" was deleted for conciseness; in
Section 4(e), "provisions" was substituted for "regulations providing"
for consistency with standard drafting conventions; in Section 4(e)(5),
"ensure" was added before "public" for clarity; in Section 5(a)(3),
"upon" was deleted for clarity; in Section 8(b)(1)(C), "addendum" was
added before "application" for consistency; in Section 8(d)(1), "to" was
added before "practitioners" for consistency; and in Section 8(j), "to"
was added after "provide" for consistency.
GL Joint Favorable Subst.